ACTC - Advanced Cell Technology, Inc. (OTC) : my favorite stock

[Phrmstx]

Advanced cell's stem cell approach to treating retinal degenerative disorders is quite unique. If the drug has a successful phase 1 trial then an orphan drug like this has HUGE potential. It is important to remember though that phase 1 trials test for treatment safety. There is, according to my data, only 12 patients enrolled in this p1 study. If any have a serious health complication as a result of this treatment than the FDA could put a hault on this development. I would wait to buy this one until after a successful phase 1 trial is announced.

[Jerico]

- Currently ACT is finalizing preclinical studies for the bio-distribution of therapeutic program addressing Retinal Degeneration (i.e. AMD or macular degeneration in the eye) and has completed GLP Safety Studies and long-term efficacy studies for the RPE therapy with positive results.

- The Company expects studies for the RPE product to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of 2009.

- Working on acquiring funding for Phase II clinical trials for the Company’s Myoblast program, an autologous (meaning “one’s own”) adult stem cell therapy for treating cardiac disease. Historically the Myoblast program successfully completed several Phase I clinical trials.

- Published positive results from HG program demonstrating hemangioblasts’ ability to repair vascular damage in animals. Therapy could be effective for treatment of blood and cardiovascular diseases. Anticipates filing an IND in 2010.

- Made progress in macular degeneration indication by reporting positive data for RPE cell animal study. Entered into collaboration with Casey Eye Institute for preclinical trials. Completed Pre-IND meeting with FDA. Expects to file IND in 2009.

- Developed and demonstrated technique to generate embryonic stems that maintain developmental potential of the embryo and therefore has potential to shift the ethical debate. Announced hESC lines created without destroying an embryo in multiple studies.

- Owns or licenses over 380 patents and patent applications related to stem cell therapy.

- Large Target Market: Regenerative Medicine has potential to treat diseases of the eye, blood disorders, heart disease, neurodegenerative diseases, liver disease, diabetes, and others.

- Led by experienced management team and scientific experts including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger *** PhD and Director of Operations Rita Parker.

[Jerico]

Agency Proposes U.S.-Paid Research on Stem Cells - NYTimes.com

This is the news we've all been waiting for. Highlights:

* "Dr. Robert Lanza, chief scientific officer of Advanced Cell Technology, said the company hopes to start clinical trials this year"

* "its clinical trial, to be conducted with the Foundation Fighting Blindness,"

* "supported by the Department of Defense"

This stock is at the bottom & will will leaving the single digits soon.
PPS at least in the .25/share range in the near term.

[newguy]

I could not trade ACTC (OTC BB) yesterday.

No new trades were listed on the trading platforms, yahoo.com, marketwatch.com, etc. However, according to otcbb.com and thehotpennystocks.com, it was being traded as usual (closing price = 0.102, volume = 3.27M). According to: Advanced Cell Technology (ACTC): davpar, yesterday I e-mailed FINRA at address below about , the stock is delisted due to MM non-compliance.

I do not understand: it is delisted yet it is being traded? Could someone explain that to me?

Does anyone have any reliable information? Is this something that can be taken care of promptly?

[newguy]

Yahoo does not show yesterday's trades under ACTC.OB, but it does under ACTC.PK.

Does this mean delisting from OTC-BB and relegation to PK?

Edited to add:

Found it! http://investorshub.advfn.com/boards...ge_id=48326732

So many stocks delisted because of the sponsoring MM's failure to pay a fee!

How long should it take to fix this?